Eugeni Lopez-Bonet
Overview
Explore the profile of Eugeni Lopez-Bonet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1089
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies
Lopez J, Llop-Hernandez A, Verdura S, Serrano-Hervas E, Martinez-Balibrea E, Bosch-Barrera J, et al.
Cell Death Discov
. 2025 Mar;
11(1):91.
PMID: 40055336
A one-two punch sequential regimen of senescence-inducing agents followed by senolytic drugs has emerged as a novel therapeutic strategy in cancer. Unfortunately, cancer cells undergoing therapy-induced senescence (TIS) vary widely...
2.
Cuyas E, Pedarra S, Verdura S, Pardo M, Espin Garcia R, Serrano-Hervas E, et al.
Cell Death Discov
. 2024 Sep;
10(1):417.
PMID: 39349429
Fatty acid synthase (FASN)-catalyzed endogenous lipogenesis is a hallmark of cancer metabolism. However, whether FASN is an intrinsic mechanism of tumor cell defense against T cell immunity remains unexplored. To...
3.
Verdura S, Encinar J, Gratchev A, Llop-Hernandez A, Lopez J, Serrano-Hervas E, et al.
Phytomedicine
. 2024 Mar;
128:155493.
PMID: 38484626
Background: ID3 (inhibitor of DNA binding/differentiation-3) is a transcription factor that enables metastasis by promoting stem cell-like properties in endothelial and tumor cells. The milk thistle flavonolignan silibinin is a...
4.
Canet-Hermida J, Marin F, Dorca E, Duenas N, Costas L, Salinas M, et al.
Mod Pathol
. 2023 Mar;
36(7):100158.
PMID: 36918055
Women with Lynch syndrome (LS) are at increased risk of endometrial cancer (EC), among other tumors, and are characterized by mismatch repair (MMR) deficiency and microsatellite instability (MSI). While risk-reducing...
5.
Temprana-Salvador J, Lopez-Garcia P, Castellvi Vives J, de Haro L, Ballesta E, Rojas Abusleme M, et al.
Diagnostics (Basel)
. 2022 Apr;
12(4).
PMID: 35453900
Complete digital pathology transformation for primary histopathological diagnosis is a challenging yet rewarding endeavor. Its advantages are clear with more efficient workflows, but there are many technical and functional difficulties...
6.
Planellas P, Cornejo L, Farres R, Pigem A, Timoteo A, Ortega N, et al.
BJS Open
. 2022 Mar;
6(2).
PMID: 35257139
No abstract available.
7.
Sanvisens A, Puigdemont M, Rubio-Casadevall J, Vidal-Vila A, Lopez-Bonet E, Martin-Romero F, et al.
Int J Environ Res Public Health
. 2021 Dec;
18(24).
PMID: 34948878
Introduction: The recent COVID-19 pandemic has compromised socio-health care, with consequences for the diagnosis and follow-up of other pathologies. The aim of this study was to evaluate the impact of...
8.
Bosch-Barrera J, Verdura S, Ruffinelli J, Carcereny E, Sais E, Cuyas E, et al.
Cancers (Basel)
. 2021 Aug;
13(16).
PMID: 34439322
The anti-angiogenic agent nintedanib has been shown to prolong overall and progression-free survival in patients with advanced non-small-cell lung cancer (NSCLC) who progress after first-line platinum-based chemotherapy and second-line immunotherapy....
9.
Verdura S, Cuyas E, Cortada E, Brunet J, Lopez-Bonet E, Martin-Castillo B, et al.
Aging (Albany NY)
. 2020 Jan;
12(1):8-34.
PMID: 31901900
New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1) are urgently needed. When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary...
10.
Lopez-Bonet E, Buxo M, Cuyas E, Pernas S, Dorca J, Alvarez I, et al.
J Clin Med
. 2019 Dec;
8(12).
PMID: 31835708
The proliferative capacity of residual breast cancer (BC) disease indicates the existence of partial treatment resistance and higher probability of tumor recurrence. We explored the therapeutic potential of adding neoadjuvant...